GLG News Analyses of the following article:
Dexamethasone implant a first for macular edema after retinal vein occlusion
Published at: ophthalmologytimes.modernmedicine.com
-
Ozurdex (Allergan) Uses Billing Structure That May Prevent Acceptance
November 9, 2009
Ozurdex (Allergan) is now on the market and available for ophthalmologists to treat patients with retinal vascular occlusions (RVO).While the technology and treatment may be sound, there may be significant hurdles to overcome from a billing standpoint.Ozurdex may follow the same fate as Lucentis (Genetech). It must compete with a much cheaper drug which has comparable efficacy.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.